SCHEMBL5010655

SCHEMBL5010655

O=C(O)c1ccc2c(c1)C(=O)N(Cc1cccc(F)c1)C2=O

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.75
HPGD P15428 2/20 0.75
MEN1 O00255 2/20 0.75
ENPP2 Q13822 1/20 0.61
CACNA1G O43497 2/20 0.61
CA1 P00915 2/20 0.57
CA4 P22748 2/20 0.57
CA2 P00918 1/20 0.57
CA9 Q16790 1/20 0.57
POLB P06746 2/20 0.56
NLRP3 Q96P20 1/20 0.54
CA12 O43570 1/20 0.53
CA7 P43166 1/20 0.53
MMP13 P45452 1/20 0.52
UBE2N P61088 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14417945 0.90 KMT2A (0.86) KMT2AHPGDMEN1ENPP2CA1
SCHEMBL5010573 0.86 KMT2A (1.00) KMT2AHPGDMEN1ENPP2CA1
SCHEMBL5010921 0.85 HPGD (0.76) KMT2AHPGDMEN1ENPP2CACNA1G
SCHEMBL5012351 0.84 KMT2A (0.75) KMT2AHPGDMEN1ENPP2CACNA1G
SCHEMBL5010625 0.84 KMT2A (0.80) KMT2AHPGDMEN1ENPP2CACNA1G
SCHEMBL22105400 0.84 KMT2A (0.70) KMT2AHPGDMEN1ENPP2CA1
SCHEMBL20010530 0.83 KMT2A (0.88) KMT2AHPGDMEN1ENPP2CA1
SCHEMBL6761908 0.83 KMT2A (0.68) KMT2AHPGDMEN1ENPP2CA1
SCHEMBL4239479 0.82 ENPP2 (0.88) KMT2AHPGDMEN1ENPP2CA1
SCHEMBL11618643 0.81 UBE2N (0.67) KMT2AMEN1CACNA1GCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319098-B2 1,3-dioxoisoindole derivatives having selective antagonism of T-type calcium channel KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2008-01-15 US disclosed
US-20070259867-A1 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259867-A1 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL CACNA1I, CACNA1G, CACNA1H KMT2A 4804/4885HPGD 1902/4885MEN1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.